Feb 24, 2026
FDA Approves Monthly Dosing for Subcutaneous Amivantamab in EGFR-Mutated NSCLC“The U.S. Food and Drug Administration has approved a once-monthly dosing schedule for frontline amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), the subcutaneous formulation of the...
Feb 17, 2026
Will Offering a Blood Test to Detect Lung Cancer Improve Screening Rates?“Dr. Melinda Aldrich wants to boost screening rates to catch lung cancer earlier when it is more treatable.” Tuberculosis, Chronic Bronchitis Linked to Lung Cancer Risk in Never-Smokers“A...
Feb 10, 2026
‘Personal lives’ of lung cancer cells help predict response to treatment“University of Queensland researchers who mapped cancer cell “neighborhoods” in the most common type of lung cancer have found cell metabolism plays a critical role in...
Feb 2, 2026
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial“In summary, our study indicates that early ToD immunochemotherapy substantially improves PFS and OS and is associated with enhanced antitumor CD8+ T cell characteristics compared...
Jan 26, 2026
Osimertinib Dose Reduction Does Not Compromise OS in EGFR-Mutated Metastatic NSCLC“Reducing osimertinib dose in the first-line treatment of EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) patients due to the occurrence of adverse events has no impact on...
